[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658509":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":25,"interventions":38,"overallOfficials":17,"centralContacts":46,"locations":52,"responsibleParty":69,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":17,"enrollmentInfo":85,"targetDuration":17,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":99,"whyStopped":17,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Phenotypic and transcriptional differences in bone marrow macrophages between CMML patients and age-matched controls","Bone marrow macrophages will be characterized by spectral\u002Fmultiparametric flow cytometry, including CD80, CD86, HLA-DR, CD163, CD206, CD209, CD200R, SIRPα and MARCO, and by targeted RT-qPCR and\u002For exploratory single-cell RNA sequencing. Differential macrophage populations and gene-expression programs will be compared between the two groups.","at inclusion",[14],{"measure":15,"description":16,"timeFrame":12},"Functional and immunomodulatory profile of bone marrow macrophages","Ex vivo cytokine secretion (including TNF-α, IL-10, CCL2 and TGF-β), phagocytosis of apoptotic or leukemic targets, modulation of naïve CD4+ T-cell polarization (Th1 versus Th2), and response to experimental pharmacological modulators targeting non-canonical caspase-8 and cathepsin B will be assessed and compared between groups",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":21,"primaryPurpose":22,"observationalModel":17,"timePerspective":17,"maskingInfo":23},"NON_RANDOMIZED","PARALLEL","Two parallel, non-randomized cohorts are enrolled: participants with confirmed CMML and age-matched controls undergoing elective total hip arthroplasty. No therapeutic intervention is assigned; study procedures consist of biological sample collection followed by ex vivo analyses.","BASIC_SCIENCE",{"masking":24,"maskingDescription":17,"whoMasked":17},"NONE",[26,32],{"label":27,"type":28,"description":29,"interventionNames":30},"CMML patients","EXPERIMENTAL","2 mL of additional bone marrow are collected during a planned standard-of-care sternal or iliac aspiration, together with 40 mL of additional peripheral blood during routine blood sampling.",[31],"Procedure: Bone marrow and blood samples",{"label":33,"type":34,"description":35,"interventionNames":36},"Control group: Age-matched controls undergoing total hip arthroplasty","ACTIVE_COMPARATOR","2 mL of bone marrow are collected from the proximal femoral metaphysis during elective total hip arthroplasty after femoral neck osteotomy, without any additional invasive procedure",[37],"Procedure: Bone marrow sample",[39,43],{"type":40,"name":41,"description":29,"armGroupLabels":42,"otherNames":17},"PROCEDURE","Bone marrow and blood samples",[27],{"type":40,"name":44,"description":29,"armGroupLabels":45,"otherNames":17},"Bone marrow sample",[33],[47],{"name":48,"role":49,"phone":50,"phoneExt":17,"email":51},"Valerie Foussat","CONTACT","+33 (0)4 92 03 63 77","foussat.v@chu-nice.fr",[53],{"facility":54,"status":17,"city":55,"state":17,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"CHU de Nice","Nice","06000","France","FR",{"type":60,"coordinates":61},"Point",[62,63],7.26608,43.70313,{"lat":63,"lon":62},[66],{"name":67,"role":49,"phone":68,"phoneExt":17,"email":17},"Thomas Cluzeau, MD PhD","+33 (0)492039025",{"type":70,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR",[72],{"name":73,"class":74},"INSERM U1065 - Centre Méditerranéen de Médecine Moléculaire (C3M)","UNKNOWN","100658509","phenotypic-and-functional-characterization-of-bone-marrow-macrophages-in-chronic-myelomonocytic-leukemia-100658509",false,"NCT07852494","Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia","Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia (CMML): Comparative Study With Age-Matched Healthy Controls","MAC-AGE","Inclusion criteria - Group Patients with CML\n\n* Age ≥ 55 years\n* Confirmed diagnosis of chronic myelomonocytic leukaemia (CML) according to WHO criteria (2022 edition)\n* Patient registered with or covered by a social security scheme\n* Bone marrow sample can be obtained during a scheduled consultation\n* Signed informed consent Exclusion criteria - Group 1\n* Active infection or acute inflammatory condition\n* Treatment with chemotherapy or immunosuppressants within the 4 weeks prior to the procedure\n* Medical contraindication to bone marrow aspiration\n* Person under guardianship, curatorship or legal protection\n* Secondary CMML\n\nInclusion criteria - Group Age-matched healthy controls\n\n* Age ≥ 55 years\n* Scheduled surgery for total hip replacement\n* No history of haematological malignancy or autoimmune disease\n* Signed informed consent\n* Patient registered with or covered by a social security scheme Exclusion criteria - Group 2\n* Active or uncontrolled chronic inflammatory condition\n* Autoimmune disease\n* Presence of a known haematological disorder, persistent monocytosis or an unexplained haematological abnormality\n* Chronic immunomodulatory or anti-inflammatory treatment\n* History of immunosuppression or chronic inflammatory disease\n* Persons under guardianship, curatorship or judicial protection","ALL","55 Years",{"count":86,"type":87},120,"ESTIMATED","INTERVENTIONAL",[90],"NA","MAC-AGE is a single-center study designed to characterize bone marrow macrophages in patients with chronic myelomonocytic leukemia (CMML) and to compare them with macrophages from age-matched controls undergoing elective total hip arthroplasty. Phenotypic, transcriptional and functional analyses will be performed using spectral\u002Fmultiparametric flow cytometry, single-cell RNA sequencing and ex vivo functional assays. The study aims to identify CMML-associated macrophage alterations and potential therapeutic targets within the bone marrow immune microenvironment.",[93],"Chronic Myelomonocytic Leukemia",[95,96,97,98],"CMML","bone marrow macrophages","single-cell RNA sequencing","spectral flow cytometry","NOT_YET_RECRUITING","2026-09-25",{"date":102,"type":103},"2026-10-01","ACTUAL",{"date":105,"type":87},"2026-11-01",{"date":107,"type":87},"2030-01-01",{"name":5,"class":6},1]